Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Core Insights - Solid Biosciences Inc. reported positive interim data for SGT-003 in the Phase 1/2 INSPIRE DUCHENNE trial, indicating a differentiated clinical profile and good tolerability among 41 participants dosed as of March 18, 2026 [1][4] - The company plans to initiate the Phase 3 IMPACT DUCHENNE trial for SGT-003 in April 2026 and is seeking FDA guidance for a potential accelerated approval pathway [1][2] - Solid has a strong capital position with $187.9 million in cash and equivalents as of December 31, 2025, and completed a $240 million private placement in March 2026, extending its cash runway into H1 2028 [1][2][4] Neuromuscular Pipeline - SGT-003 is designed for Duchenne muscular dystrophy and has shown robust microdystrophin expression and improvements in muscle integrity biomarkers and cardiac function [4][9] - The first participant in the Phase 1b FALCON trial for SGT-212 (Friedreich's Ataxia) has been dosed, with no treatment-related adverse events reported [1][7] - The Phase 1b ARTEMIS trial for SGT-501 (CPVT) has activated clinical sites, with first participant dosing expected in Q2 2026 [1][7] Financial Performance - R&D expenses for Q4 2025 were $38.1 million, up from $30.8 million in Q4 2024, with a total of $140.3 million for the full year 2025 compared to $96.4 million in 2024 [15][19] - General and administrative expenses for Q4 2025 were $11.3 million, compared to $9.1 million in Q4 2024, totaling $38.9 million for the full year 2025 [15][19] - The net loss for Q4 2025 was $49.8 million, compared to a net loss of $42.6 million in Q4 2024, with a total net loss of $174.3 million for the full year 2025 [15][19]